Capitol Hill House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget June 12, 2026Vol.52 No.23By Paul Goldberg
As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick labThe job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded June 12, 2026Vol.52 No.23By Paul Goldberg
FreeTrials & Tribulations Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy June 12, 2026Vol.52 No.23By Peter F. Garrett
Sponsored Survivorship begins at diagnosis—cancer care system must recognize this June 12, 2026Vol.52 No.23By Saro Armenian
Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival June 05, 2026Vol.52 No.22By Jacquelyn Cobb
Trials & Tribulations The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe June 05, 2026Vol.52 No.22By W. Kimryn Rathmell
Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final June 05, 2026Vol.52 No.22By Paul Goldberg and Claire Marie Porter
At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer June 05, 2026Vol.52 No.22By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg
Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.” June 05, 2026Vol.52 No.22By Claire Marie Porter
